The Sucheck Group works at the interface of synthetic carbohydrate chemistry, chemical biology, and antimicrobial discovery. We develop new methods for the synthesis of oligosaccharides, glycoconjugates, and glycomimetics, with an emphasis on practical strategies that enable the preparation of structurally defined bacterial carbohydrates for bioconjugation, vaccine studies, and chemical biology. Our research also focuses on the design of small molecules that disrupt carbohydrate-processing and cell-wall biosynthetic pathways in important bacterial pathogens, including Mycobacterium tuberculosis and Pseudomonas aeruginosa. By combining synthetic innovation with biologically important targets such as GlgE, Ag85, and Pks13, we aim to advance both fundamental glycobiology and new approaches to infectious disease therapeutics.